Shortly after, there were widespread reports of patients with rheumatoid arthritis and other inflammatory diseases on Actemra's label struggling to get access to their treatment. As supplies ...

No new safety signals were observed and these results are consistent with Actemra’s safety profile in rheumatoid arthritis. An ongoing 104-week open label extension study is ongoing, and will pr ...

Explore the expanding Actemra market, fueled by rising autoimmune disease prevalence and increasing adoption in treatment protocols worldwide. The Actemra drug market is estimated to be valued at ...